Today's Stocks Driving Success For The Drugs Industry

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 63 points (0.4%) at 15,199 as of Monday, July 8, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,878 issues advancing vs. 1,083 declining with 93 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 1.0%. Top gainers within the industry include Allergan ( AGN), up 2.8%, Sanofi ( SNY), up 1.1%, Teva Pharmaceutical Industries ( TEVA), up 0.9%, AstraZeneca ( AZN), up 0.7% and GlaxoSmithKline ( GSK), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.32 (0.9%) to $35.24 on average volume. Thus far, 4.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $34.94-$35.36 after having opened the day at $34.95 as compared to the previous trading day's close of $34.92.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $53.4 billion and is part of the health care sector. Shares are up 6.6% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Eli Lilly and Company ( LLY) is up $0.41 (0.8%) to $50.99 on light volume. Thus far, 2.0 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $50.66-$51.10 after having opened the day at $50.80 as compared to the previous trading day's close of $50.58.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $56.5 billion and is part of the health care sector. Shares are up 2.6% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Amgen ( AMGN) is up $0.69 (0.7%) to $98.33 on light volume. Thus far, 1.1 million shares of Amgen exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $98.10-$99.22 after having opened the day at $98.46 as compared to the previous trading day's close of $97.64.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $71.9 billion and is part of the health care sector. Shares are up 13.3% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.58 (0.7%) to $88.45 on average volume. Thus far, 4.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 10.1 million shares. The stock has ranged in price between $87.97-$88.99 after having opened the day at $88.09 as compared to the previous trading day's close of $87.87.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $243.8 billion and is part of the health care sector. Shares are up 25.3% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.18 (0.6%) to $28.14 on light volume. Thus far, 15.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 63.0 million shares. The stock has ranged in price between $28.08-$28.30 after having opened the day at $28.24 as compared to the previous trading day's close of $27.97.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $195.4 billion and is part of the health care sector. Shares are up 11.5% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy